Fairness in Orphan Drug Exclusivity Act

The House passed the Fairness in Orphan Drug Exclusivity Act (H.R. 1629) to fix the nation’s orphan drug development rules that are exploited; however, its facing opposition in the Senate. Orphan drugs treat rare diseases, affecting under 200,000 people in the U.S., or there is no reasonable expectation that production costs could be recouped via sales. Orphan drugs qualify for seven years of exclusivity, which means a drug originator retains exclusive rights to manufacture and distribute the drugs for a specified duration. Read the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org